Skip to content

Up, Down, and All Around: Evaluating Mobility Devices for Young Children With Developmental Disabilities and Delays

Up, Down, and All Around: Evaluating Mobility Devices for Young Children With Developmental Disabilities and Delays

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06591559
Enrollment
16
Registered
2024-09-19
Start date
2025-02-11
Completion date
2026-03-30
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Palsy, Down Syndrome, Gross Motor Delay

Keywords

early intervention, mobility aid, powered mobility, partial bodyweight support

Brief summary

This research study will examine young children with Down syndrome's initial experiences with mobility devices. Children's biomechanics and exploration will be quantified while they are using both an overground partial bodyweight support system and powered mobility device.

Detailed description

Young children with Down syndrome experience delays in cognition, communication, and mobility. As a result of cerebellar hypoplasia, children with Down syndrome have altered balance and coordination, muscle hypotonia, decreased muscle strength, and ligament laxity. Low muscle tone and ligament laxity can lead to the adoption of unfavorable postures, putting children at risk for developing musculoskeletal disorders in the future. While children with Down syndrome are expected to walk, they do so significantly later than their peers, creating a gap in mobility, exploration, and socialization in the first years of life. Mobility during the first years is crucial to facilitate cascades of reciprocal development in cognition, communication, and motor skills, as well as reduce developmental delays and participation disparities for children with Down syndrome compared to their peers. While early intervention is common during this time to facilitate movement, clinical practice patterns vary widely and there are few evidence-based interventions or assistive technologies to support children and their families. Treadmill training is currently the only intervention that has demonstrated efficacy for young children with hypotonia, but only for improving walking speed among already ambulatory children. Traditional treadmill training is limited, however, in that it does not allow for the sensorimotor experiences and social interactions that occur with self-initiated mobility in enriched, and often unpredictable, natural environments. As such, treadmill training and other clinical interventions may not fully address the need for holistic and multi-modal mobility opportunities. Augmented mobility - in the form of partial bodyweight support systems, gait trainers, and powered mobility - has been proposed as a promising and complementary intervention to support early development in Down syndrome. While these tools have the potential to bridge the gap in self-initiated mobility and accelerate the onset of independent walking, little is scientifically known about how children engage with these devices nor how these devices shape their interactions with their environment. Furthermore, there is a lack of knowledge concerning the impact of different mobility devices on a child's physical development and posture. In this research, the investigators propose to quantify a child's exploration, posture, and motor control strategies while using two promising assistive technologies for pre-ambulatory young children with Down syndrome: a partial-bodyweight support system (PUMA, Enliten, LLC.) and a powered mobility device (Explorer Mini, Permobil) that can be used in both seated and standing postures. Participants will attend a total of four play sessions where they will play with a) no devices, b) partial bodyweight support, c) in the Explorer Mini in a standing posture, and d) in the Explorer Mini in a seated posture.

Interventions

The Explorer Mini (Permobil AB, Sweden) is a commercially available, FDA approved powered mobility device intended for young children between 12-36 months of age with mobility limitations (weight limit: 35 lbs; height limit: 39.4 inches). It is lightweight (52 lbs. including battery) and fits in most automobiles (length: 25 inches; width: 19 inches; adjustable height: 29-37 inches). The Explorer Mini runs on a 12-volt battery with a driving range of 3.5 miles and a maximum speed of 1.5 mph, is controlled via a joystick with a 360-degree turning radius, has proportional speed control with 5 speed options, and can be used in a seated or standing position.

DEVICEPortable Mobility Aid for Children (PUMA)

The Portable Mobility Aid for Children (PUMA; Enliten LLC) is a portable canopy system that utilizes an overhead support rail structure and a counterweight. The rail structure consists of two rigid parallel beams that mount to the canopy structure and one perpendicular mobile beam that allows for freedom of movement in one direction. Freedom of movement in the opposite direction is achieved by a system of pulleys along the movable beam that connects the harness to a counterweight. The counterweight provides a passive vertical force, counteracting gravity. The PUMA provides 2-dimensional mobility support over 81 ft2 (9 ft x 9 ft). The overhead bar is connected at 4 points to a child-worn harness. Children are free to move through many postures including sitting, crawling, standing, and walking.

Sponsors

University of Washington
Lead SponsorOTHER
National Center for Advancing Translational Sciences (NCATS)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
12 Months to 60 Months
Healthy volunteers
No

Inclusion criteria

* are able to sit upright independently * are able to tolerate moving through space while upright for 30 minutes * are under 35 pounds in weight * are under 39 inches tall in height * developmental delays and conditions that affect mobility and muscle tone

Exclusion criteria

\- are able to walk 10 ft independently

Design outcomes

Primary

MeasureTime frameDescription
Percentage of space exploredAt the end of each 30-minute play session for each study arm (session 1, session 2, session 3, session 4)The path of each child's movement during the play sessions will be tracked from video recordings and sensor data. The path will then be used to determine the percentage of the available play space that the child explored. Values will range from 0 - 100%, a higher value indicates more space explored.

Secondary

MeasureTime frameDescription
Normalized Integrated Electromyography (EMG)At the end of each 30-minute play session for each study arm (session 1, session 2, session 3, session 4)Children will wear electromyography (EMG) sensors while playing. We will measure the bilateral muscle activity of the tibialis anterior, gastrocnemius, quadriceps, hamstrings (biceps femoris), erector spinae, and cervical paraspinal using surface EMGs. EMG data will be high-pass filtered (40 Hz), rectified, and low-pass filtered (10 Hz) to create a linear envelope of muscle activity during play sessions. For each muscle group, we will calculate the integrated EMG signal, or area under the curve, for each session normalized by time in device. Values will range from 0 to 100%, higher values indicate more muscle activity.
Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST) 2.1: Children VersionAt the end of each 30-minute play session for each study arm (session 1, session 2, session 3, session 4)The QUEST 2.1: Children Version is an extension of the original QUEST tool tailored specifically for children who use assistive technology. The primary aim of this test is to evaluate how well assistive technology devices meet the needs of children and enhance their overall satisfaction with these devices. The questionnaire is designed to gather information on various aspects of the assistive technology, including its functionality, ease of use, and impact on the life of the user.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORHeather A Feldner, PhD, PT, PCS

University of Washington

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 5, 2026